Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 12/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166101 | 0.88 | MBOAT4 (0.61) | MBOAT4 | |
| SCHEMBL18154016 | 0.87 | MBOAT4 (0.50) | MBOAT4LMNASMN1; SMN2LDHA | |
| SCHEMBL18166114 | 0.87 | MBOAT4 (0.66) | MBOAT4OPRK1 | |
| SCHEMBL16699213 | 0.87 | MBOAT4 (0.69) | MBOAT4CHRM4OPRK1 | |
| SCHEMBL19971866 | 0.86 | MBOAT4 (0.70) | MBOAT4SMN1; SMN2LDHA | |
| SCHEMBL18166212 | 0.84 | MBOAT4 (0.55) | MBOAT4LMNASMN1; SMN2LDHA | |
| SCHEMBL18166111 | 0.84 | MBOAT4 (0.59) | MBOAT4LMNASMN1; SMN2 | |
| SCHEMBL19971863 | 0.84 | MBOAT4 (0.58) | MBOAT4SMN1; SMN2LDHA | |
| SCHEMBL18166110 | 0.83 | MBOAT4 (0.57) | MBOAT4SMN1; SMN2LDHA | |
| SCHEMBL19971783 | 0.83 | MBOAT4 (0.53) | MBOAT4SMN1; SMN2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-22 | — | — | US | disclosed |
| EP-3283474-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | Eli Lilly and Company (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168225-A1 | GHRELIN O-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227310-B2 | Ghrelin 0-acyl transferase inhibitors | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885LMNA 4700/4885SMN1; SMN2 4346/4885 |
| US-20180079729-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | MBOAT4 1/4885LMNA 4700/4885SMN1; SMN2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.